J
Jason Martin Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
13 h-index
52 pubs
1,302 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Jason Martin's research program focuses on several distinct areas, including advanced cancer treatments, plant pathology, and educational studies. His recent publications highlight work on TAR-200, an investigational therapy for Bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer, with results from the SunRISe-1 study presented in multiple 2025 publications. He also contributed to studies on apalutamide for prostate cancer and reported on the conversion of corn stover biomass to bio-ethanol in a 2021 final report.
In addition to clinical and bio-refinery research, Martin investigates educational topics. A 2022 publication explores the relationship between intellectual need and undergraduate students' learning of calculus. His federally funded research includes a $943,941 NSF CAREER award focused on dissecting the molecular regulation of septin-mediated plant invasion by the blast fungus Magnaporthe Oryzae, with Martin serving as Principal Investigator (PI). His scholarly output includes 54 publications, with 1,286 citations and an h-index of 13.
Metrics
- h-index: 13
- Publications: 52
- Citations: 1,302
Selected Publications
-
Attentive fidelity and the coordination of attentive and conceptual processes in learning from mathematics videos lessons (2026)
-
Interactions between cognitive disequilibrium, interactivity with instructional videos, and learning (2025)
-
Teaching practice aimed at promoting student engagement with metarules of defining (2024)
-
Observing Intellectual Need and its Relationship with Undergraduate Students’ Learning of Calculus (2022)
Federal Grants 1 $943,941 total
Collaboration Network
Top Collaborators
Évanguelos Xylinas
7 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
Showing 5 of 7 shared publications
Giuseppe Simone
7 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
Showing 5 of 7 shared publications
Shalaka Hampras
7 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
Showing 5 of 7 shared publications
Hussein Sweiti
7 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
Showing 5 of 7 shared publications
Joseph M Jacob
6 shared publications
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
- Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
Showing 5 of 6 shared publications
Andrea Necchi
6 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
Showing 5 of 6 shared publications
Siamak Daneshmand
6 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
Showing 5 of 6 shared publications
Daniel Zainfeld
6 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
Showing 5 of 6 shared publications
Abhijit Shukla
6 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
Showing 5 of 6 shared publications
Michiel S. van der Heijden
6 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
Showing 5 of 6 shared publications
Philipp Spiegelhalder
6 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
Showing 5 of 6 shared publications
Félix Guerrero‐Ramos
5 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
- Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
Yair Lotan
5 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
- Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
David Cahn
5 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
- Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
Christopher J. Cutie
5 shared publications
- TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
- Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
- TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE PAPILLARY DISEASE–ONLY HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: FIRST RESULTS FROM COHORT 4 OF SUNRISE-1
- SAFETY AND TOLERABILITY OF TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN (BCG)-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) IN SUNRISE-1
Similar Researchers
Based on overlapping research topics
R. L. Stone
University of Arkansas – Fort Smith
Cancer Treatment and Pharmacology
Higher Education Research Studies
Immune Response and Inflammation
lan J Tackett
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Kona Blake Swift
University of Arkansas at Fayetteville
Plant Pathogens and Fungal Diseases
Agronomic Practices and Intercropping Systems
Osman O Atiq
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Nishanth Thalambadu
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Farah Mazahvreh
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation